P0985: Real-world experience of subcutaneous infliximab use in children with inflammatory bowel disease (IBD) at a tertiary paediatric centreECCO'25Year: 2025
Authors: Eldredge, J.(1);Kaur, R.(2);Tano, M.(3);Chidgey, T.(3);Singh, N.(3,4);Chuah, C.W.(3);Magoffin, A.(3);Thacker, K.(3);O'Loughlin, E.(3);Dutt, S.(3,5)*;
(1)The Children's Hospital at Westmead, Department of Gastroenterology and Hepatology, Westmead, Australia;(2)University of Sydney, Faculty of Medicine and Health, Sydney, Australia;(3)The Children's Hospital at Westmead, Department of Gastroenterology and Hepatology, Sydney, Australia;(4)The Children's Hospital at Westmead, Pharmacy Department, Sydney, Australia;(5)University of Sydney, Children's Hospital Westmead Clinical School- Sydney School of Medicine, Sydney, Australia;
1) Schreiber S, Ben-Horin S, Leszczyszyn J et al. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology 2021; 160: 2340-53.
2) Buisson A, Nachury M, Bazoge M et al. Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: The REMSWITCH-LT study. Aliment Pharmacol Ther 2024; 59: 526-34.
3) Gianolio L, Armstrong K, Swann E et al. Effectiveness of Switching to Subcutaneous Infliximab in Pediatric Inflammatory Bowel Disease Patients on Intravenous Maintenance Therapy. J Pediatr Gastroenterol Nutr 2023; 77: 235-9.
4) Gianolio L, Armstrong K, Swann E et al. OC5 Effectiveness and safety of switching to subcutaneous infliximab in paediatric inflammatory bowel disease patients on established intravenous biosimilar infliximab maintenance therapy: real world data from a regional cohort. Frontline Gastroenterology 2024; 15: A4-A.
P0986: Sequencing of biological therapies and impact on persistence: Report from a tertiary referral centerECCO'25Year: 2025
Authors: Amato, L.M.(1)*;Antoci, C.(1);Melatti, P.(1);Di Giorgio, F.(1);Salerno, I.A.(1);Ajovalasit, R.(1);Di Prima , L.(1);Bracciamà, E.(1);Scalia, S.(1);Celsa , C.(1);Cappello, M.(1);
(1)University of Palermo - Section of Gastroenterology and Hepatology, Department of Health Promotion-Mother and Child Care-Internal Medicine and Medical Specialties PROMISE, Palermo, Italy; University of Palermo
P0987: Muscle function deficits in Crohn's Disease patients treated with Infliximab - tertiary single centre experienceECCO'25Year: 2025
Authors: Spirić, J.(1)*;Vuksanovic, S.(1);Toplicanin, A.(1);Nikolic, A.(1);Jovicic, T.(1);Jovicic, I.(1);Djuranovic, S.(1,2);Popovic, D.(1,2);Pavlovic Markovic, A.(1,2);Djelic, M.(2,3);Sokic-Milutinovic, A.(1,2);
(1)University Clinical Centre of Serbia, Clinic for Gastroenterohepatology, Belgrade, Serbia;(2)University of Belgrade, School of Medicine, Belgrade, Serbia;(3)University of Belgrade, Institute of Medical Physiology „Rihard Burijan”, Belgrade, Serbia;
P0988: Dose-Dependent Incidence of Acne in Korean Patients Treated with UpadacitinibECCO'25Year: 2025
Authors: Lee, J.(1)*;Kim, S.J.(1);Lee, M.H.(1);
(1)College of Medicine- Chosun University, Division of gastroenterology- Department of Internal medicine, Gwangju, Korea- Republic Of;
1. Temido MJ, Honap S, Bursztejn AC, et al. Drug-Induced Acne in Inflammatory Bowel Disease: A Practical Guide for the Gastroenterologist. Am J Gastroenterol 2024.Online ahead of print.
P0989: Interventions for rheumatological extraintestinal manifestations in Inflammatory Bowel Disease: an umbrella review of systematic reviewsECCO'25Year: 2025
Authors: Nardone , O.M.(1)*;Alajmi , A.(2,3);Yuan , Y.(2);Jairath , V.(2,3,4);
(1)University of Naples Federico II, Department of Public Health, Naples, Italy;(2)Western University, Department of Medicine- Division of Gastroenterology, London- Ontario, Canada;(3)Western University, Department of Epidemiology & Biostatistics, London- Ontario, Canada;(4)Lawson Health Research Institute, London Health Science Center, London- Ontario, Canada;
P0990: Real-world effectiveness of upadacitinib induction therapy in Crohn’s disease, with a focus on patients with concomitant IMIDsECCO'25Year: 2025
Authors: Elosua Gonzalez, A.(1)*;Zabalza, L.(1);Vicuña, M.(1);Rubio, S.(1);Nantes, Ó.(1);Rodriguez, C.(1);
(1)Hospital Universitario de Navarra, Gastroenterology, Pamplona, Spain;
P0991: Laparoscopic ileocecal resection in pediatric Crohn's disease: effect of anastomotic configuration on postoperative outcomes in the era of biologic therapyECCO'25Year: 2025
Authors: Dotlacil, V.(1)*;Lerchova, T.(2,3);Kucerova, B.(1);Schwarz, J.(4);Hradsky, O.(3);Skaba, R.(1);Rygl, M.(1);
(1)Second Faculty of Medicine- Charles University and Motol University Hospital, Department of Paediatric Surgery, Prague, Czech Republic;(2)Institute of clinical science- Sahlgrenska academy- University of Gothenburg, Department of Pediatrics, Gothenburg, Sweden;(3)Second Faculty of Medicine- Charles University and Motol University Hospital, Department of Paediatrics, Prague, Czech Republic;(4)Faculty of Medicine in Pilsen- Faculty Hospital- Charles University in Prague, Department of Paediatrics, Pilsen, Czech Republic;
P0992: Real-world experience of faecal microbiota transplant in ulcerative colitisECCO'25Year: 2025
Authors: Povlsen, S.(1)*;Merrick, B.(2);Yeo, J.H.(3);Samaan, M.(1);Goldenberg, S.(2);
(1)Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;(2)Guy's and St Thomas' NHS Foundation Trust- King's College London, Centre for Clinical Infection and Diagnostics Research, London, United Kingdom;(3)University College London Hospitals NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom;
1Mullish BH, Merrick B, Quraish MN, et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut 2024;73:1-24.
2Imdad A, Pandit NG, Zaman M, Minkoff NZ, Tanner-Smith EE, Gomez-Duarte OG, Acra S, Nicholson MR. Fecal transplantation for treatment of inflammatory bowel disease. Cochrane Database of Systematic Reviews 2023; 4(CD012774). DOI: 10.1002/14651858.CD012774.pub3. Accessed 18 November 2024.
P0993: Prevention of Postoperative Recurrence of Crohn's Disease: Comparison of Two Therapeutic Strategies.ECCO'25Year: 2025
Authors: Amal, J.(1)*;Abdelwahab, N.(1);myriam, A.(2);zeineb, B.(1);nesrine, H.(1);bochra, B.(1);taieb, J.(2);rym, E.(1);Med Hedi, D.(2);
(1)Mongi Slim Hospital, Gastroenterology, Tunis, Tunisia;(2)FSI Hospital, gastroenterology, Tunis, Tunisia;
P0994: Effectiveness of Risankizumab in an Emirati Crohn’s Disease Cohort: Real-World Insights on Induction, Maintenance, and Dose Intensification OutcomesECCO'25Year: 2025
Authors: Alzaabi, M.N.(1)*;Swaid, T.K.(1);Ahmed, H.A.(1);Alahmed, M.A.(1);Omar, N.M.(1);Kumar, K.K.C.(1);Ahmed, E.F.(1);Malik, T.A.(2);Quraishi, M.N.(1);
(1)Sheikh Shakhbout Medical City, Gastroenterology, Abu Dhabi, United Arab Emirates;(2)Mayo Clinic Arizona, Gastroenterology, Arizona, United States;
P0995: Use of biologics before ileal pouch-anal anastomosis is not associated with inflammatory pouch diseaseECCO'25Year: 2025
Authors: Yan, Y.(1)*;Wang, F.(2);We, J.(2);Gong, J.(3);
(1)Jinling Hospital- Affiliated Hospital of Medical School- Nanjing University, Department of Gastroenterology and Hepatology, Nanjing- Jiangsu- China, China;(2)Jinling Hospital- Affiliated Hospital of Medical School- Nanjing University, Department of Gastroenterology and Hepatology-, Nanjing- Jiangsu- China, China;(3)Jinling Hospital- Affiliated Hospital of Medical School- Nanjing University, Department of General Surgery, Nanjing- China., China;
P0996: JAK Inhibitors Open a New Chapter in IBD Treatment: a Monocentric Retrospective Observational ResearchECCO'25Year: 2025
Authors: Fu, X.(1)*;Zhu, L.(1);
(1)Union Hospital- Tongji Medical College- Huazhong University of Science and Technology, Department of Gastroenterology, Wuhan, China;
1.Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399(10341):2113-2128. doi:10.1016/S0140-6736(22)00581-5
2.Loftus EVJ, Panés J, Lacerda AP, et al. Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease. New England Journal of Medicine. 2023;388(21). doi:10.1056/NEJMoa2212728
P0997: The Rectal Stump during and after subtotal colectomy for Ulcerative Colitis: A scoping review of surgical strategies, medical management options and cancer surveillance recommendationsECCO'25Year: 2025
Authors: Argyriou , O.(1,2)*;Ghersin , I.(3);Stravodimos , G.(1);Worley , G.(1,2);Tozer , P.(1,2);Hart , A.(3,4);Sahnan , K.(1,2);
(1)St Mark's the National Bowel Hospital, Department of Colorectal Surgery, London, United Kingdom;(2)Imperial College London, Department of Surgery and Cancer, London, United Kingdom;(3)St Mark's the National Bowel Hospital, Department of Gastroenterology, London, United Kingdom;(4)Imperial College London, Department of Gastroenterology, London, United Kingdom;
P0998: Mucosal Healing and Long-Term Medication Survival in Crohn's Disease Patients Treated with Anti-TNF TherapyECCO'25Year: 2025
Authors: Lopes, M.(1)*;de Queiroz Prado Bittencourt, N.(1);Furieri Rigo, F.(1);Souza de Oliveira, E.C.(1);Soares Prates Herrerias, G.(1);Pinheiro Baima, J.(1,2);Yukie Sassaki, L.(1);
(1)São Paulo State University- Medical School, Internal medicine, Botucatu, Brazil;(2)Uninove Bauru, Internal Medicine, Bauru, Brazil;
P0999: Efficacy and safety of different biologics in first line therapy in Crohn’s disease: a multicentric retrospective comparative analysisECCO'25Year: 2025
Authors: Preda, C.M.(1)*;Podgoreanu, B.(2);Trifan, A.(3);Tantau, A.(4);Negreanu, L.(5);Tieranu, C.(6);Bucurica, S.(7);Minea, H.(8);Buzuleac, M.(9);Popescu, R.(5);Bota, A.(10);Istratescu, D.(1);Stroie, T.(1);Tugui, L.(2);Diculescu, M.(1);
(1)UMF Carol Davila, Department of Gastroenterology and Hepatology- Clinical Fundeni Institute, Bucharest, Romania;(2)Clinical Fundeni Institute, Department of Gastroenterology and Hepatology, Bucharest, Romania;(3)Faculty of General Medicine- University of Medicine and Pharmacy “Gr. T. Popa”- Iași, Department of Gastroenterology and Hepatology, Iasi, Romania;(4)“Iuliu Hatieganu” University of Medicine and Pharmacy- The 4th Medical Clinic CF Hospital- Cluj-Napoca, Department of Internal Medicine and Gastroenterology, Cluj, Romania;(5)UMF Carol Davila, Department of Gastroenterology and Hepatology- Emergency Universitary Hospital, Bucharest, Romania;(6)UMF Carol Davila, Department of Gastroenterology and Hepatology- Elas Emergency Hospital, Bucharest, Romania;(7)UMF Carol Davila, Department of Gastroenterology and Hepatology- Central Military Hospital, Bucharest, Romania;(8)aculty of General Medicine- University of Medicine and Pharmacy “Gr. T. Popa”, Department of Gastroenterology and Hepatology, Iasi, Romania;(9)Faculty of General Medicine- University of Medicine and Pharmacy “Gr. T. Popa”, Department of Gastroenterology and Hepatology, Iasi, Romania;(10)UMF Carol Davila, Department of Gastroenterology and Hepatology- Elias Emergency Hospital, Bucharest, Romania;
P1000: A quasi-experimental study evaluating effectiveness of partial enteral nutrition combined with exclusion diet in patients with mild to moderately severe ulcerative colitisECCO'25Year: 2025
Authors: Vuyyuru, S.(1)*;Madan, D.(1);Kante, B.(1);Goswami, S.(2);Kumar, P.(1);Kumar Ranjan, M.(1);Mundhra, S.(1);Golla, R.(1);Singh, N.(1);Ranjan Dash, N.(3);Sharma, R.(4);Das, P.(5);Makharia, G.(1);Shankar Ghosh, T.(2);Kedia, S.(1);Ahuja, V.(1);
(1)All India Institute of Medical Sciences, Department of Gastroenterology and Human Nutrition, New Delhi, India;(2)Indraprastha Institute of Information Technology, Department of Computational Biology, New Delhi, India;(3)All India Institute of Medical Sciences, Department of Gastrointestinal surgery, New Delhi, India;(4)All India Institute of Medical Sciences, Department of Radiodiagnosis, New Delhi, India;(5)All India Institute of Medical Sciences, Department of Pathology, New Delhi, India;
P1001: Efficacy and safety of an oral tyrosine kinase 2 inhibitor VTX958 in moderately to severely active Crohn’s disease: a randomised, double-blind, placebo-controlled, phase 2 trialECCO'25Year: 2025
Authors: Danese, S.(1)*;Jairath, V.(2);Sands, B.E.(3);Schreiber, S.(4);Panaccione, R.(5);D'Haens, G.(6);Lindstrom, B.(7);Liu, K.(7);Sandborn, W.(8);Rubin, D.T.(9);Peyrin-Biroulet, L.(10);Vermeire, S.(11);Naik, S.(7);
(1)IRCCS Ospedale San Raffaele- Vita-Salute San Raffaele University, Department of Gastroenterology and Endoscopy, Milan, Italy;(2)Western University, Department of Medicine- Division of Gastroenterology, London, Canada;(3)Icahn School of Medicine at Mount Sinai, Dr Henry D Janowitz Division of Gastroenterology, New York, United States;(4)Hospital Schleswig-Holstein- Kiel University, Department Internal Medicine I, Kiel, Germany;(5)University of Calgary, Inflammatory Bowel Disease Unit- Division of Gastroenterology and Hepatology, Calgary, Canada;(6)Amsterdam University Medical Centers, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(7)Ventyx Biosciences Inc., Clinical Development, San Diego, United States;(8)University of California, Division of Gastroenterology, San Diego, United States;(9)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(10)University of Lorraine- Inserm- NGERE, Department of Gastroenterology, Nancy, France;(11)University Hospitals Leuven, Department of Gastroenterology & Hepatology, Leuven, Belgium;
P1002: Changes in circulating lymphocyte subsets and CCR9 transcripts as mechanistic biomarkers of the small molecule α4β7 inhibitor MORF-057 in patients with Ulcerative ColitisECCO'25Year: 2025
Authors: Hussain, A.(1)*;Singhal, P.(1);Wong, J.(2);Goodwin, B.(3);Abhyankar, B.(4);Soo, C.(5);Rogers, B.(6);Mangada, M.(1);
(1)Morphic Therapeutic- a wholly owned subsidiary of Eli Lilly and Company, Translational Sciences, Waltham, United States;(2)Morphic Therapeutic- a wholly owned Subsidiary of Eli Lilly and Company, Immunology, Waltham, United States;(3)Morphic Therapeutic- a wholly owned Subsidiary of Eli Lilly and Company, Biology & Translational Sciences, Waltham, United States;(4)Morphic Therapeutic- a wholly owned Subsidiary of Eli Lilly and Company, Clinical Development, Waltham, United States;(5)Morphic Therapeutic- a wholly owned Subsidiary of Eli Lilly and Company, Clinical Operations, Waltham, United States;(6)Morphic Therapeutic- a wholly owned Subsidiary of Eli Lilly and Company, Research, Waltham, United States;
1.Hussain A, et al. Increase in circulating T and B lymphocyte subsets after treatment with the potent, selective, oral small molecule α4β7 inhibitor MORF-057 in healthy subjects. UEG Week; 2022 Oct 8-11; Vienna, Austria.
2.Ray A, et al. MORF-057, an oral selective α4β7 integrin inhibitor for inflammatory bowel disease, leads to specific target engagement in a single and multiple ascending dose study in healthy subjects. ECCO Congress; 2021 July 7-10; Virtual. ePoster 306.
P1003: The shorter the interval between preconceptional disease activity and pregnancy, the greater the risk of disease activity during pregnancy: Evidence from a large Dutch cohortECCO'25Year: 2025
Authors: Bouwknegt, D.G.(1)*;Dijkstra, G.(1);van Dop, W.A.(2);van der Woude, C.J.(2);Visschedijk, M.C.(1);
(1)University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands;(2)Radboud University Medical Center, Gastroenterology and Hepatology, Nijmegen, The Netherlands; Dutch Initiative on Crohn and Colitis (ICC)
1. Tandon P, Govardhanam V, Leung K, Maxwell C, Huang V. Systematic review with meta-analysis: risk of adverse pregnancy-related outcomes in inflammatory bowel disease. Aliment Pharmacol Ther. 2020;51(3):320-333. doi:10.1111/apt.15587
2. Leung KK, Tandon P, Govardhanam V, Maxwell C, Huang V. The Risk of Adverse Neonatal Outcomes with Maternal Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2021;27(4):550-562. doi:10.1093/ibd/izaa122
3. Kim MA, Kim YH, Chun J, et al. The Influence of Disease Activity on Pregnancy Outcomes in Women with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. J Crohns Colitis. 2021;15(5):719-732. doi:10.1093/ecco-jcc/jjaa225
P1004: The Effects of a Dual-Strain Probiotic Versus Placebo on the Microbiome in Patients with Ulcerative ColitisECCO'25Year: 2025
Authors: Carroll, A.(1)*;Walker, C.(1);Magdeldin, H.(1);Ryan, B.(1);O'Donnell, S.(1);McNamara, D.(1);Breslin, N.(1);Corr, S.(2);O'Connor, A.(1);
(1)Tallaght University Hospital, Gastroenterology, Dublin, Ireland;(2)Trinity College Dublin, Microbiology, Dublin, Ireland;
1. Römkens TEH, van Vugt-van Pinxteren MWJ, Nagengast FM, van Oijen MGH, de Jong DJ. High prevalence of fatigue in inflammatory bowel disease: A case control study. Journal of Crohn's and Colitis. 2011;5(4):332-7.
2. Sokol H, Seksik P, Rigottier-Gois L, Lay C, Lepage P, Podglajen I, et al. Specificities of the fecal microbiota in inflammatory bowel disease. Inflammatory bowel diseases. 2006;12(2):106-11.
3. Du L, Ha C. Epidemiology and Pathogenesis of Ulcerative Colitis. Gastroenterology Clinics of North America. 2020 2020/12/01/;49(4):643-54.
4. Frank DN, St. Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proceedings of the National Academy of Sciences. 2007;104(34):13780-5.
